Article, News
Prescient’s PTX-100 granted FDA’s Orphan Drug Designation for all T-cell lymphomas
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of 7 years. The US FDA has just granted Prescient Therapeutics (ASX:PTX)’s…
Article, News
Prescient Therapeutics receives FDA orphan drug status for PTX-100 to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US Food and Drug Administration (FDA) for its lead candidate PTX-100…
Article, News
Prescient Therapeutics (ASX:PTX) reports progress in cancer studies during H1 FY23 – Kalkine Media
Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) — focused on the development of novel and personalised cancer-related therapies — has released its half-year report for…
Article, News
PTX-100 shows encouraging efficacy signals and safety in area of high unmet clinical need
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage assets across CAR-T and targeted cell therapies. The company has…
Article, News
Breakthrough cancer therapies develop while traditional treatments remain prevalent
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy and radiation. Each poses their own benefits, risks and limitations….
Article, News
Prescient (ASX:PTX) ends last quarter on firm financial footing and key clinical developments – Kalkine Media
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving player for the next generation of personalised therapies for cancer.
Article, News
Topped up with cash, Prescient presses on in US$280 billion industry
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by the World Health Organisation, but in the same year nearly…
Article, News
Inside Prescient Therapeutics’ (ASX:PTX) clinical progress to cancer treatment
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to address significant unmet needs. The company’s development portfolio comprises cell…
Article, News
Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. …
Article, News
Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a partial response, meaning the size of the cancer tumour has…